Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) EBITDA Margin (2016 - 2025)

Arcadia Biosciences' EBITDA Margin history spans 12 years, with the latest figure at 152.61% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 3481.0% year-over-year to 152.61%; the TTM value through Dec 2025 reached 51.42%, up 2085.0%, while the annual FY2025 figure was 51.46%, 2085.0% up from the prior year.
  • EBITDA Margin reached 152.61% in Q4 2025 per RKDA's latest filing, down from 88.48% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 248.55% in Q1 2021 to a low of 313.88% in Q1 2023.
  • Average EBITDA Margin over 5 years is 73.15%, with a median of 102.76% recorded in 2022.
  • The largest YoY upside for EBITDA Margin was 344741bps in 2021 against a maximum downside of -56828bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 215.3% in 2021, then surged by 134bps to 73.02% in 2022, then plummeted by -310bps to 153.54% in 2023, then dropped by -22bps to 187.42% in 2024, then increased by 19bps to 152.61% in 2025.
  • Per Business Quant, the three most recent readings for RKDA's EBITDA Margin are 152.61% (Q4 2025), 88.48% (Q3 2025), and 34.43% (Q2 2025).